CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Bruce Ruggeri, Craig A. Dionne, Susan Jones‐Bolin, Kathryn Hunter, John T. Isaacs(Brady (Norway)), John P. Mallamo, Paweł Dobrzański, Bernard Bourie(Johns Hopkins University), Robert L. Hudkins(State Street (United States)), Mark A. Ator, Mark S. Albom, Andres J. Klein–Szanto, Lisa D. Aimone, Paul Schaeffer, Pierre Casellas(Université de Montpellier), Françoise Bono(OSE Immunotherapeutics (France)), Candy Robinson, Hong Chang, Роберто Пили(Jacobs Institute), Thelma S. Angeles, Diane E. Gingrich
PubMed
September 15, 2003
Cited by 124
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic Steatosis
|PLoS Biology|2005|942
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
|Proceedings of the National Academy of Sciences|2008|723